You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
|
|---|---|
| Published in |
BMC Cancer, July 2012
|
| DOI | 10.1186/1471-2407-12-292 |
| Pubmed ID | |
| Authors |
Leonie JM Mekenkamp, Jolien Tol, Jeroen R Dijkstra, Inge de Krijger, M Elisa Vink-Börger, Shannon van Vliet, Steven Teerenstra, Eveline Kamping, Eugène Verwiel, Miriam Koopman, Gerrit A Meijer, J Han JM van Krieken, Roland Kuiper, Cornelis JA Punt, Iris D Nagtegaal |
| Abstract |
KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influence of modification of KRAS by gene copy number aberration (CNA) and microRNAs (miRNAs) in correlation to clinical outcome in mCRC patients treated with cetuximab in combination with chemotherapy and bevacizumab. |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Germany | 1 | 1% |
| Belgium | 1 | 1% |
| Unknown | 92 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 23% |
| Student > Ph. D. Student | 15 | 16% |
| Student > Master | 15 | 16% |
| Other | 12 | 13% |
| Professor > Associate Professor | 4 | 4% |
| Other | 13 | 14% |
| Unknown | 15 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 40% |
| Agricultural and Biological Sciences | 22 | 23% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 17 | 18% |